ORMP Oramed Pharmaceuticals Inc. featured news, full reports, and detailed charts
Oramed Pharmaceuticals Inc. (ORMP/ORMP.OB) Wrap Up:
Oramed Pharmaceuticals, Inc., a development stage company, engages in the research and development of pharmaceutical solutions. The company is developing orally ingestible insulin pill capsules for the treatment of individuals with diabetes. It also focuses on conducting research and development of other pharmaceutical solutions, including rectal application of insulin, flu vaccines, use of oral ingestible pills for delivery other polypeptides, and use of rectal application for delivery of other polypeptides. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals, Inc. in 2006. Oramed Pharmaceuticals is based in Jerusalem, Isra...www.oramed.com
Founded in 2002
Oramed Pharmaceuticals Inc. (ORMP:OTC Bulletin Board Market)
LAST $0.48 USD
CHANGE TODAY 0.00 0.00%
VOLUME 2.2K
As of 3:56 PM 11/20/09 All times are local (Market data by Reuters is delayed by at least 15 minutes).
Snapshot of Oramed Pharmaceuticals Inc. (ORMP)
|
OPEN
$0.46
|
PREVIOUS CLOSE
$0.48
|
|
|
DAY HIGH
$0.48
|
DAY LOW
$0.46
|
|
|
52 WEEK HIGH
09/10/09 - $0.64
|
52 WEEK LOW
03/3/09 - $0.20
|
|
|
MARKET CAP
27.1M
|
AVERAGE VOLUME 3 mo
35.3K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
56.5M
|
|
|
ORMP Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ORMP Top Compensated Officers
Mr. Nadav Kidron
Chief Executive Officer, President and Execut...
Age: 35
Total Annual Compensation: $151.0K
Ms. Miriam Kidron
Chief Medical & Technology Officer, Chief Sci...
Age: 69
Total Annual Compensation: $145.4K
Executives, Board Directors
Compensation as of Fiscal Year 2008.
Key developments for Oramed Pharmaceuticals Inc. (ORMP)
Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
09/9/2009
Oramed Pharmaceuticals Inc. announced that it has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog. This approval was granted after successful pre-clinical results were reported. The trials will be conducted on healthy volunteers at Hadassah University Medical Center in Jerusalem. Currently, all GLP-1 Analogs are only available as injections. The oral administration of GLP-1 Analogs may convey physiological advantages for diabetic patients, as the hormone mimics the physiological route of incretin absorption. GLP-1 Analogs belongs to the Incretin family of drugs which have pleiotropic effects desirable in the management of diabetes. Among the more important effects are the insulinotropic effects and resultant reduction in blood glucose levels, the inhibition of glucagon secretion and the restoration of beta cell mass. GLP-1 Analogs are also associated with weight loss, which is very desirable in patients with diabetes. Oramed is currently conducting Phase 2b clinical trials of its flagship product, ORMD-0801, an oral insulin capsule.
Oramed Pharmaceuticals Inc. - Conference Presentation Call
09/3/2009
To discuss company's strategic initiatives, updates and product pipeline.
Oramed Pharmaceuticals Inc. - Conference Presentation Call
08/18/2009
To present an overview of the clinical development of the company's Oral Insulin capsule
ORMP Competitors
| Company | Last | Change |
| Apollo Consolidated Limited | A$0.01 AUD | -0.002 |
| Aradigm Corp | $0.16 USD | +0.005 |
| Emisphere Technologies | $0.67 USD | 0.00 |
| Generex Biotechnology Corp | $0.50 USD | -0.01 |
| MannKind Corp | $6.88 USD | -0.06 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ORMP | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 9.4x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
ORMP |
||
ORMP transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent News About Oramed Pharmaceuticals Inc.
More news for ORMP
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Show all filings for ORAMED PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ORAMED PHARMACEUTICALS INC. 21-Oct-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provi...Click here to read the whole Article (external link)
Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
JERUSALEM, September 9 /PRNewswire-FirstCall/ -- Oramed Pharmaceticals, Inc. (OTCBB: ORMP.OB - News), a developer of oral drug delivery systems, announced today that it has received approval from the Institutional Review Board (IRB) to commence human clinical trials of an oral GLP-1 Analog. This approval was granted after successful pre-clinical results were reported. The trials will be conducted on healthy volunteers at Hadassah University Medical Center in Jerusalem. Currently, all GLP-1 Analogs are only available as injections. The oral administration of GLP-1 Analogs may convey physiological advantages for diabetic patients, as the hormone mimics the physiological route of incretin absorption.GLP-1 Analogs belongs to the Incretin family of drugs which have pleiotropic effects desirable in the management of diabetes. Among the more important effects are the insulinotropic effects and resultant reduction in blood glucose levels, the inhibition of glucagon secretion and the restoration of beta cell mass. GLP-1 Analogs are also associated with weight loss, which is very desirable in patients with diabetes."The move from preclinical trials to human clinical trials of ORMD-0901 marks a strategic milestone for the company. We have expanded our platform technology and will now have the opportunity to demonstrate its effectiveness in another important family of polypeptide drugs for diabetes, which is currently only available in injection form," said Oramed CEO Nadav Kidron.Oramed is currently condu...Click here to read the whole Article (external link)
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Show all filings for ORAMED PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ORAMED PHARMACEUTICALS INC. 9-Sep-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided...Click here to read the whole Article (external link)
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure,
Show all filings for ORAMED PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ORAMED PHARMACEUTICALS INC. 3-Sep-2009Change in Directors or Principal Officers, Regulation FD Disclosure, Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All infor...Click here to read the whole Article (external link)
Oramed Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference
JERUSALEM, September 3 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB - News; http://www.oramed.com), a developer of alternative drug delivery systems, announced today that Nadav Kidron, its Chief Executive Officer, is scheduled to present at the Rodman & Renshaw's 11th Annual Healthcare Conference on Friday September 11, 2009 at 10:00 a.m. EDT. The conference will be held at the New York Palace Hotel in New York City. Nadav Kidron is scheduled to speak in the Fahnestock Salon on the fifth floor of the hotel. He will discuss Oramed's strategic initiatives, updates and product pipeline.About Oramed PharmaceuticalsOramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.For more information, please visit ...Click here to read the whole Article (external link)
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Show all filings for ORAMED PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ORAMED PHARMACEUTICALS INC. 25-Aug-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provi...Click here to read the whole Article (external link)
Frost and Sullivan Honors Oramed Pharmaceuticals With the 2009 European Oral Drug Delivery Technology Innovation Award
JERUSALEM, August 25 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB - News; http://www.oramed.com), a developer of oral delivery systems, today announced that it is the recipient of the 2009 Frost & Sullivan European Oral Drug Delivery Technology Innovation Award. Oramed Pharmaceuticals is developing a platform technology to create oral delivery systems for drugs and vaccines delivered via injection. Oramed focuses on the treatment of diabetes through its proprietary flagship product, an Oral Insulin capsule that is currently in Phase 2b clinical trials. Oramed's research pipeline also includes other product candidates, such as an Oral GLP-1 Analog capsule."We are honored to receive the 2009 European Oral Drug Delivery Technology Innovation Award," said Nadav Kidron, Esq., Oramed's CEO. "Being recognized for our leadership position in the oral drug delivery field by Frost & Sullivan is an encouraging validation of our progress.Frost & Sullivan's Technology Innovation Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service and strategic product development. Industry analysts compare market participants and meas...Click here to read the whole Article (external link)
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Show all filings for ORAMED PHARMACEUTICALS INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for ORAMED PHARMACEUTICALS INC. 19-Aug-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provide...Click here to read the whole Article (external link)
Would you like to leave a comment about Oramed Pharmaceuticals Inc. ORMP/ORMP.OB
Find out what social network information about Oramed Pharmaceuticals Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Oramed Pharmaceuticals Inc. there is more great information available at Realpennies.com